Actively Recruiting
New Treatment for Nocturnal Enuresis in Children
Led by Sohag University · Updated on 2024-07-12
450
Participants Needed
1
Research Sites
35 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to evaluate the role of sulbutiamine in treatment of monosymptomatic nocturnal enuresis in children by using it alone or as a combination therapy with tricyclic antidepressants (imipramine+sulbutiamine).
CONDITIONS
Official Title
New Treatment for Nocturnal Enuresis in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 6 and 18 years old
- Diagnosed with primary monosymptomatic nocturnal enuresis (bedwetting without other urinary symptoms) within this age range
You will not qualify if you...
- Secondary nocturnal enuresis (child who was dry for at least 6 months before bedwetting started)
- Congenital urinary tract anomalies (e.g., posterior urethral valve, ectopic ureter, ectopia vesica)
- History of previous lower urinary tract surgery (e.g., multiple hypospadias surgeries)
- Neurogenic bladder conditions such as underactive bladder or urge incontinence
- Presence of post-void residual urine greater than 20% of bladder capacity
- History or evidence of diseases in other organs such as cardiovascular disease, liver disease, psychological problems
- Known allergic reaction to either of the study medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sohag Faculty of Medecine
Sohag, Egypt
Actively Recruiting
Research Team
L
loai mohammed abd alhamied, resident
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here